To evaluate the safety and efficacy of two doses of recombinant zoster vaccine（RZV）in normal immune population over 50 years of age in Nanchang.

1 802 people over 50 years old who received two doses of RZV were selected as the observation group, and 2 132 people were simultaneously inoculated with Pneumococcal Vaccine Polyvalent（PPV23）and Quadrivalent influenza vaccines（QIV）in subjects over 50 years of age served as a control group. The incidence of adverse reactions and the incidence of Herpes zoster（HZ）within 1 year after vaccination were analyzed and compared between the observation group and the control group after vaccination.

In the observation group, the incidence of adverse reactions was 23.89%, the incidence of adverse reactions at inoculation site, abnormal vital signs and non-inoculation site were 16.79%, 9.05% and 7.69%, and the incidence of grade 1 and grade 2 adverse reactions were 22.42% and 1.47%. The incidence of adverse reactions in control group was 8.72%, the incidence of adverse reactions at inoculation site, abnormal vital signs and non-inoculation site were 7.38%, 2.06% and 1.17%, and the incidence of grade 1 and grade 2 adverse reactions were 7.60% and 1.13%. There were statistically significant differences in the incidence of adverse reactions between the observation group and the control group（χ²=187.817-339.938, P<0.05）, but there was no significant difference in the incidence of grade 2 adverse reactions（χ²=0.109-1.833, P>0.05）. Within one year after vaccination, the incidence of HZ was 0.33% in the observation group and 1.45% in the control group. The estimated vaccine effectiveness（VE）after two doses of RZV vaccine was 77.82%（95% CI:47.07%-90.70%）.

Two doses of RZV were highly effective. Although the incidence of adverse reactions is high but the degree is mild, it has a good safety.